Q1 2021 13F Holders as of 31 Mar 2021
-
Type / Class
-
Equity / Common shares
-
Shares outstanding
-
250,425,788
-
Number of holders
-
90
-
Total 13F shares, excl. options
-
60,314,515
-
Shares change
-
+5,223,993
-
Total reported value, excl. options
-
$141,778,049
-
Value change
-
+$12,436,479
-
Put/Call ratio
-
363%
-
Number of buys
-
48
-
Number of sells
-
-26
-
Price
-
$2.35
Significant Holders of Lineage Cell Therapeutics, Inc. - Common shares (LCTX) as of Q1 2021
105 filings reported holding LCTX - Lineage Cell Therapeutics, Inc. - Common shares as of Q1 2021.
Lineage Cell Therapeutics, Inc. - Common shares (LCTX) has 90 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 60,314,515 shares
of 250,425,788 outstanding shares and own 24.08% of the company stock.
Largest 10 shareholders include BROADWOOD CAPITAL INC (34,005,379 shares), VANGUARD GROUP INC (5,559,504 shares), Defender Capital, LLC. (4,950,720 shares), BlackRock Inc. (2,463,488 shares), Prescott General Partners LLC (1,851,851 shares), TWO SIGMA ADVISERS, LP (1,633,866 shares), MILLENNIUM MANAGEMENT LLC (1,425,776 shares), GEODE CAPITAL MANAGEMENT, LLC (1,265,951 shares), TWO SIGMA INVESTMENTS, LP (1,254,531 shares), and SUSQUEHANNA INTERNATIONAL GROUP, LLP (1,000,182 shares).
This table shows the top 90 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.